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Although it has become increasingly clear that cancers display extensive cellular
heterogeneity, the spatial growth dynamics of genetically distinct clones within developing
solid tumours remain poorly understood. Here we leverage mosaic analysis with double
markers (MADM) to trace subclonal populations retaining or lacking p53 within oncogenic
Kras-initiated lung and pancreatic tumours. In both models, p53 constrains progression to
advanced adenocarcinomas. Comparison of lineage-related p53 knockout and wild-type
clones reveals a minor role of p53 in suppressing cell expansion in lung adenomas.
In contrast, p53 loss promotes both the initiation and expansion of low-grade pancreatic
intraepithelial neoplasia (PanINs), likely through differential expression of the p53
regulator p19ARF. Strikingly, lineage-related cells are often dispersed in lung adenomas and
PanINs, contrasting with more contiguous growth of advanced subclones. Together, these
results support cancer type-speciﬁc suppressive roles of p53 in early tumour progression and
offer insights into clonal growth patterns during tumour development.
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C
ancer cells within developing tumours exhibit signiﬁcant
genetic and phenotypic heterogeneity mediating tumour
growth, metastasis and therapy resistance1–3. This
intratumoral heterogeneity is thought to arise from the
sequential accumulation of genetic or epigenetic changes that
favour the growth of distinct subclonal populations. Indeed,
construction of genetic hierarchies from genomic sequencing data
reveals the presence of subclonal populations within individual
tumours that propagate throughout progression from early to
advanced primary tumours and metastases4–7. Studies in
transplant models have underscored the functional importance
of speciﬁc genetic variants in modulating growth dynamics of
different subclones within tumours8,9. Unfortunately, similar
analyses in physiologically relevant, autochthonous cancer
models during tumour progression are lacking10 due to
technical challenges in inducing sequential mutations in
subclonal populations and unambiguously tracing them at
single-cell resolution.
We have previously developed autochthonous models of lung
and pancreatic cancer by simultaneous Cre recombinase-
mediated activation of oncogenic Kras (KrasG12D) and biallelic
inactivation of p53 in cells residing in the tissues of origin11–13.
These models faithfully recapitulate certain prevalent genetic
alterations, histologic tumour progression, metastatic behaviour
and treatment response of the human diseases. By comparing
LSL-KrasG12D/KrasWT; p53WT/WT and LSL-KrasG12D/KrasWT;
p53ﬂox/ﬂox mice infected with inhaled adenovirus carrying Cre
recombinase, our laboratory revealed a role of p53 in limiting
tumour progression from low-grade lung adenomas to advanced
adenocarcinomas11. Furthermore, reactivation of p53 in advanced
lung tumours led to selective loss of adenocarcinoma cells14,15,
consistent with a speciﬁc role of p53 mutation in regulating
late-stage lung tumour progression. Finally, exome-sequencing
analyses of murine lung adenocarcinomas derived from
LSL-KrasG12D/KrasWT; p53ﬂox/ﬂox mice revealed no recurrent
mutations beyond Kras and p53 (ref. 16), suggesting that p53 loss
is the main genetic driver of tumour progression in this model.
Previous studies have also suggested that p53 principally plays
a role late in pancreatic tumorigenesis. Similar to what is seen in
human lung tumours17, p53 mutations are primarily observed in
more advanced human pancreatic lesions, including pancreatic
ductal adenocarcinoma (PDAC) or precursor PanINs of high-
grade histology18,19. Moreover, p53 mutation shortens the latency
and increases the frequency of PDAC formation in mouse
pancreatic tumour models in which p53 is simultaneously
mutated at the time of oncogenic Kras activation13,20.
In this study, we adapt these models to permit sequential and
sporadic p53 loss of heterozygosity (LOH) following oncogenic
Kras-mediated tumour initiation. We more faithfully model
clonal evolution during tumorigenesis and perform high-resolu-
tion tracing of subclones lacking or retaining p53 during tumour
progression. We demonstrate that sporadic p53 loss promotes
progression to advanced lung and pancreatic tumours. Moreover,
we conﬁrm that p53 primarily plays a role late in lung
tumorigenesis. In contrast, we determine that p53 suppresses
both the initiation and expansion of early pancreatic tumours,
which correlates with expression of the p53 regulator p19ARF.
Finally, we show surprisingly signiﬁcant intratumoral cell
dispersion of subclones in early lung and pancreatic tumours.
Results
Induction of p53 LOH using MADM in mice. To generate
sporadic p53 LOH in Kras-initiated tumors, we took advantage of
mosaic analysis with double markers (MADM), which permits
simultaneous ﬂuorescence cell labelling and mutagenesis through
a single Cre-mediated inter-chromosomal recombination event in
mice21. MADM has been used to study the consequence of
tumour suppressor gene LOH on tissue development and cancer
initiation at single-cell resolution22,23. We crossed LSL-KrasG12D
mice with MADM11-GT,p53WT/MADM11-TG,p53KO mice to
generate LSL-KrasG12D/KrasWT; MADM11-GT,p53WT/MADM11-
TG-p53KO mice (K-MADM-p53) (Methods). On Cre expression,
oncogenic Kras is efﬁciently induced via intra-chromosomal
Cre-mediated recombination permitting tumour initiation
(Fig. 1a). Sporadic p53 LOH occurs by subsequent stochastic
and inefﬁcient Cre-mediated inter-chromosomal recombination
between homologous chromosomes. Mitotic recombination and
X segregation (G2-X) of the MADM cassettes is predicted to
result in the generation of two genotypically and phenotypically
distinct daughter cells from a colourless p53KO/WTparent cell:
GFPþ /tdTomato (green) p53KO/KO and GFP /tdTomatoþ
(red) p53WT/WT (Fig. 1a,b and Supplementary Fig. 1). In contrast,
G2-Z, G0 or G1 recombination results in the generation
of GFPþ /tdTomatoþ (yellow) and GFP /tdTomato
(colourless) p53KO/WT cells (Fig. 1b,c and Supplementary
Fig. 1). As the ﬂuorescent markers are genetically encoded, the
MADM system affords tracing of lineage-related green p53KO/KO
and red p53WT/WT subclones, allowing for the induction and
monitoring of intratumoral heterogeneity in autochthonous
tumours.
Sporadic p53 LOH promotes progression to lung adenocarcinoma.
To determine whether sporadic and sequential (following Kras
mutation) p53 LOH promotes lung tumour progression, we
administered lentiviral Cre via the trachea to adult K-MADM-p53
mice to induce stable Cre expression in lung epithelial cells24.
Infected mice exhibited multiple small lung tumours containing
ﬂuorescently labelled cells, although green (p53KO/KO) cells did
not predominate at early time points (Fig. 2a). Mice analysed at
later time points, however, displayed an increase in the overall
size of tumours and the development of larger and more
numerous green tumours. Histologic analysis of these large
tumours revealed high-grade lesions (adenocarcinomas) con-
sisting of densely packed green cells (Fig. 2b). We also observed
mixed-grade tumours (mixed adenoma–adenocarcinomas) in
which the adenocarcinoma component was entirely green
(Fig. 2c). These data suggest that the sequential loss of p53 is a
driver of tumour progression to adenocarcinoma in oncogenic
Kras-initiated lung tumours.
We conﬁrmed these ﬁndings using an alternative, less
efﬁcient MADM model in which Kras-initiated lung tumours
spontaneously arise through a Cre-independent stochastic
recombination event (KrasLA2 model)25 and MADM-labelled
clones are thereafter generated by tamoxifen-induced Cre
activation (CreERT2) (Fig. 3a). This method ensures sequential
mutation of p53 following tumour initiation by oncogenic Kras.
From eight KrasLA2,Rosa26-CreERT2/KrasWT; MADM-p53 mice
dissected following the development of tumour-related morbidity,
we observed two ﬂuorescently labelled tumours on whole mount
analysis (Fig. 3b). These tumours were green (p53KO/KO) and
displayed histologic features of adenocarcinoma (Fig. 3c). In
addition, a small number of low-grade adenomas harboured rare
yellow p53KO/WT cells (Fig. 3d), supporting the inefﬁcient nature
of MADM recombination in this model and the clonality of the
green tumour cells. No ﬂuorescently labelled tumours were
observed on whole mount analysis of lungs from ten
KrasLA2,Rosa26-CreERT2/KrasWT; MADM mice (lacking p53
mutation). Together, these data are consistent with a role of
p53 in constraining lung tumour progression to adenocarcinoma.
p53 loss does not greatly impact early lung tumorigenesis.
To further evaluate whether p53 also suppresses cell expansion in
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early lung tumours, we classiﬁed lung adenomas based on their
green or red cell predominance in tissue sections of K-MADM-
p53 mice at 10–16 weeks post infection (p.i.) (Fig. 4a). As green
and red cells are produced at 1:1 stoichiometry following a single
G2-X recombination event (Fig. 1a), green cells should out-
number red cells in these tumours (green-dominant) if p53 loss
promotes cell expansion during early tumorigenesis. In contrast, a
plurality of tumours (51 of 132) showed no colour dominance on
qualitative analysis of random cross-sections of adenomas. Given
the possibility for stochastic differences in individual daughter
cell expansion following G2-X recombination, we did observe
tumours (69 of 132) that showed green or red cell
predominance. However, the proportions of green-dominant and
red-dominant tumours were not statistically different, suggesting
that green p53KO/KO cells did not have a selective growth
advantage at this stage (Fig. 4b). To more rigorously characterize
the ratio of green to red cells (green-to-red ratio) within
individual tumours, we quantiﬁed labelled cells across serial
sections through entire lung adenomas derived from mice
dissected 10 or 16 weeks p.i. Again, we observed no difference in
the intratumoral proportions of p53KO/KO and p53WT/WT cells at
10 weeks p.i. and only a small difference at 16 weeks p.i.
(Fig. 4c,d). These results indicate that p53 loss does not
signiﬁcantly affect tumour cell expansion in lung adenomas.
Given the stochastic nature of mitotic recombination events
leading to MADM labelling, we were unable to deﬁnitively
determine the timing of p53 loss in K-MADM-p53 mice. To
circumvent this limitation, we used the sum of all red and green
single-labelled cells in a tumour as a surrogate for timing of G2-X
recombination with the assumption that increased overall cell
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labelling indicates earlier time points of p53 LOH. If the duration
of p53 loss altered cell expansion, we would expect a positive
correlation between the total number of single-labelled cells and
the green-to-red ratio. Interestingly, there was no association
between these two parameters in lung adenomas (Fig. 4e).
Together, these data conﬁrm earlier work11,14,15 demonstrating
that p53 loss does not have a signiﬁcant impact on early lung
tumorigenesis.
p53 LOH drives tumour progression to PDAC. To evaluate the
effect of p53 LOH on pancreatic tumour progression using
MADM, we crossed K-MADM-p53 mice with Pdx1-Cre mice to
direct Cre expression to the developing pancreas12. Pdx1-Cre-
MADM-p53 mice (lacking LSL-KrasG12D) exhibited green, red
and yellow acinar, ductal and islet cells but no overt cellular
phenotypes due to p53 loss (Fig. 5a and Supplementary Fig. 2). In
contrast, Pdx1-Cre-K-MADM-p53 mice developed the full
spectrum of pancreatic tumour progression from low-grade
(Fig. 5b) and high-grade PanINs (Fig. 5c) to advanced PDAC
(Fig. 5d) and occasionally distant metastases (Fig. 5e,f).
Interestingly, Pdx1-Cre-K-MADM-p53 mice exhibited a median
survival of B11 weeks, falling in between that observed in
Pdx1-Cre; LSL-KrasG12D/KrasWT (KC) mice harbouring
homozygous p53 mutation (B6 weeks) and heterozygous p53
mutation (B16 weeks) (Fig. 5g), supporting p53 LOH as an
important driver of tumour progression in this model. Consistent
with p53 constraining progression to advanced disease, high-
grade PanINs and PDACs were predominantly or completely
green at an intermediate time point (6 weeks) (Fig. 6a,b). We
conﬁrmed this green predominance of advanced lesions in intact
pancreata using CLARITY tissue clearing26 (Fig. 6c,d).
p53 suppresses PanIN initiation and expansion. To determine
the consequence of p53 loss on tumour initiation in pancreatic
cancer, we took advantage of the fact that G2-X recombination
and labelling could occur during pancreatic development
(as Pdx1-Cre is expressed as early as E8.5 (ref. 12)) before
transformation, resulting in PanINs comprising cells of uniform
colour. We ﬁrst conﬁrmed that there was no difference in the
proportions of green and red normal duct cells, the putative
cell-of-origin for PanINs19. Next, we quantiﬁed the number
of low-grade PanINs harbouring all green or all red cells in
6-week-old Pdx1-Cre-K-MADM-p53 mice (Fig. 7a). Interestingly,
we observed a greater frequency of all-green PanINs (Fig. 7b),
suggesting that p53 loss promoted pancreatic tumour initiation by
oncogenic Kras. We also evaluated the role of p53 on cell
expansion in low-grade tumours by analysing the proportion of
incompletely labelled low-grade PanINs (G2-X recombination
occurring after tumour initiation) containing predominantly
green or red cells (Fig. 7c). Unlike our observations in early
lung tumours, we found increased numbers of green-dominant
compared with red-dominant low-grade PanINs (Fig. 7d),
consistent with enhanced cell expansion following p53 loss in
early pancreatic tumours. Overall, these ﬁndings suggest a
potential tumour suppressive role of p53 throughout oncogenic
Kras-mediated pancreatic tumorigenesis, contrasting with mainly
late functions during lung tumour progression.
To explore the mechanism behind p53-mediated suppression
of cell expansion, we assessed proliferation (pulse EdU incorpora-
tion) and apoptosis (cleaved caspase-3) by immunostaining tissue
sections of pancreatic and lung tumours. The percentage of
p53KO/KOcells exhibiting EdU incorporation was signiﬁcantly
increased compared with p53WT/WT cells in low-grade PanINs
(Supplementary Fig. 3a). In contrast, apoptosis was rare, largely
limited to cells detached into the lumen and not related to cells of
a particular p53 genotype (Supplementary Fig. 3b). As low-grade
lung tumours displayed low levels of overall proliferation, few
p53WT/WT and p53KO/KO cells were co-labelled with EdU with no
10 weeks p.i. 16 weeks p.i. 20 weeks p.i. 24 weeks p.i.
a
b c
Figure 2 | p53 constrains lung tumour progression in the LSL-KrasG12D-MADM model. (a) Whole-mount images of K-MADM-p53 mice at various time
points following lentiviral Cre administration displaying p53KO/KO (green, GFPþ/tdTomato-), p53WT/WT (red, GFP-/tdTomatoþ ) and p53KO/WT (yellow, GFPþ/
tdTomatoþ ) cells within lung tumours. p.i., post infection. (b) Lung adenocarcinomas consisting mostly of green cells. (c) Mixed-grade tumour consisting of
adenoma (left) and adenocarcinoma cells (right). The adenocarcinoma component consists of all green cells. Blue, DAPI-stained nuclei. Scale bars, 200mm (all).
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obvious difference in the percentages of labelled cells
(Supplementary Fig. 3c). High-grade p5KO/KO tumours showed
much greater EdU incorporation (Supplementary Fig. 3d,e),
whereas apoptosis was not observed in lung tumours
(Supplementary Fig. 3f). Together, these data suggest that p53
loss promotes cell cycle progression in early pancreatic tumours.
Differential expression of p19ARF-p53 during tumorigenesis.
We hypothesized that differences in the timing of induction or
stabilization of p53 protein expression may account for the
functional differences observed between the tumour types. As
wild-type p53 is difﬁcult to detect by immunohistochemistry
(IHC) on tissue sections with currently available antibodies,
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we took advantage of oncogenic Kras-driven lung and pancreatic
cancer models harbouring a p53R172H mutant allele (LSL-KrasG12D;
LSL-p53R172H), which demonstrate similar histologic progression
to the MADM models11,20. In these mice, mutant p53 is stabilized,
due in part to loss of feedback inhibition, and serves as a marker of
endogenous p53 expression27. Consistent with our hypothesis, we
observed p53 protein expression in pancreatic but not lung cells
during all stages of tumorigenesis from acinar-to-ductal metaplasia
and low-grade PanINs to advanced disease (Fig. 8).
Previous work from our laboratory has suggested that tissue-
speciﬁc expression of p19ARF, a positive upstream regulator of
p53, could alter the response to oncogenic Kras in tumour
initiation28. Using LSL-KrasG12D; LSL-p53R172H mice, we
observed expression of p19ARF in early- and late-stage
pancreatic lesions in similar pattern to p53 expression (Fig. 9a).
In contrast, lung adenocarcinomas, but not adenomas, expressed
p19ARF (Fig. 9b). As p53 mutant cells may induce p19ARF by
loss of negative feedback28, we veriﬁed that p19ARF expression
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Figure 4 | p53 loss does not signiﬁcantly have an impact on early lung tumorigenesis. (a) Lung adenomas from K-MADM-p53mice 16 weeks p.i. showing
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(b) Absolute quantiﬁcation of observed green-dominant and red-dominant lung adenomas in K-MADM-p53 mice (10–16 weeks p.i., n¼ 5 mice total).
Expected numbers are based on 1:1 stoichiometric ratio of green and red cell generation, and stochastic growth thereafter. No statistical difference was
observed (P40.05, w2-test). A plurality of tumours (51 of 132) did not exhibit colour dominance. (c) Absolute quantiﬁcation of green and red cells across
individual tumours derived from K-MADM-p53 mice evaluated at 10 weeks p.i. (n¼9) and 16 weeks p.i. (n¼8). (d) Geometric means (±95% conﬁdence
intervals) of green-to-red cell ratio in lung tumours (based on data from c, n¼9 at 10 weeks p.i. and n¼8 at 16 weeks p.i.). Line represents equal green and
red cell numbers (ratio¼ 1). The green-to-red cell ratio is mildly but signiﬁcantly increased in tumours from 16-week-old mice (* denotes 95% conﬁdence
interval does not cross unity). (e) No statistically signiﬁcant correlation between green-to-red cell ratio and total single-labelled (green plus red) cells per
tumour was observed (P40.05, linear regression).
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was observed in early pancreatic tumours even in the context of
wild-type p53 (Fig. 9c). These data suggest that the p19ARF-p53
axis may play a role in suppressing early pancreatic
tumorigenesis. This observation is compatible with the
decreased capacity of oncogenic Kras to initiate pancreatic
tumours compared with lung tumours in mice29. When we
examined the lungs and pancreata of KrasLA2 mice, which
undergo stochastic somatic activation of oncogenic Kras
throughout the mouse25, 48/48 (100%) mice harboured lung
tumours, but only 1/48 (2%) had PanIN lesions.
Extratumoral invasion of PanIN cells. In addition to pursuing
quantitative analyses of tumour cell expansion, we also used the
MADM models to monitor the spatial relationships between
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PDAC from 6-week-old Pdx1-Cre-K-MADM-p53 mice show uniform green
(GFPþ/tdTomato , p53KO/KO) labelling in these advanced lesions. Blue,
DAPI-stained nuclei. Scale bars, 100mm. (b) Absolute quantiﬁcation of
high-grade PanINs/PDAC in 6-week-old Pdx1-Cre-K-MADM-p53mice (n¼ 5
mice total). Expected numbers are based on 1:1 stoichiometric ratio of green
and red cell generation, and were not observed (Po0.001, w2-test).
(c) CLARITY image of pancreas from a 13-week-old Pdx1-Cre-K-MADM-p53
mouse showing grossly diseased pancreas (PanINs interspersed with
normal pancreatic tissue) without overt PDAC. Right image shows zoomed
in area from left image. Scale bars, 1mm (left image) and 100mm (right
image). (d) CLARITY image of PDAC from a 13-week-old Pdx1-Cre-
K-MADM-p53 mouse. Right image shows zoomed in area from left image.
Scale bars, 1mm (left image) and 100mm (right image).
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lineage-related cells during tumour progression. Using MADM,
we observed green mesenchymal-like cells nearby but dispersed
from green high-grade PanINs, some of which had lost
expression of the epithelial marker cytokeratin 19 (Fig. 10a), in
6-week-old Pdx1-Cre-K-MADM-p53 mice. Given the low
frequency of high-grade PanINs or PDACs at this time point
(B2.2 lesions per pancreas section per mouse), these invasive
cells are likely to be derived from the PanIN epithelial cells.
These ﬁndings are consistent with extratumoral invasion and
epithelial-to-mesenchymal transition during putative preinvasive
PanIN stages and corroborate previous work using Pdx1-Cre;
LSL-KrasG12D/KrasWT; p53ﬂox/WT mice harbouring a LSL-YFP
reporter30. Moreover, as MADM induces G2-X recombination
sporadically at low efﬁciency, it offers a much more stringent
evaluation of clonally related cells than traditional Cre/loxP-based
reporters that may be prone to aberrant reporter expression from
leaky transgenic Cre lines31.
Intratumoral cell dispersion in early tumours. Aside from the
extratumoral spread of cells from putative preinvasive tumours
in the pancreas, we also observed remarkable intratumoral
dispersion of lineage-related cells in early lung and pancreatic
tumours. Rather than exclusively displaying adjacent clusters of
expanding green and red cells as would be expected with the
stationary growth of epithelial tumour cells, lung adenomas and
low-grade PanIN lesions often displayed subclones in which
cells were non-contiguous in tissue sections (Fig. 10b–d).
We conﬁrmed this cell dispersal in three dimensions by analysing
intact tissues using multi-photon microscopy (Fig. 10e,f and
Supplementary Movies 1–4).
To quantitatively assess cell dispersal, we calculated the mean
distance between different green or red cells in tissue sections of
lung adenomas from K-MADM-p53 mice at 10-16 weeks p.i.
Although labelled cells of the same colour were separated
by an average of B8.7 cell diameters (range 2.47–27.76, n¼ 31
tumours), p53KO/KO cells surprisingly exhibited signiﬁcantly
decreased dispersal than p53WT/WT cells (7.2 versus 10.2 cell
diameters, P¼ 0.013, two-tailed paired Student’s t-test). Indeed,
as p53KO/KO tumour cells progress, they appear to form more
densely packed clones (Figs 2b,c and 3c). Together, these data
support a model in which early tumours display subclonal
dispersed growth, whereas tumour progression afforded by p53
loss promotes more localized growth.
Discussion
In this study, we have used MADM to trace genetically distinct
subclones within the same tumours to parse speciﬁc roles of p53
during different stages of lung and pancreatic tumor-
igenesis and to elucidate dynamic subclonal growth patterns in
early epithelial tumours. MADM has several advantages over
pre-existing mouse models of cancer. Unlike early models that
induced simultaneous cooperating mutations in large numbers of
cells11,12,32, MADM permits sporadic and sequential mutagenesis
of oncogenes and tumour suppressor genes, more faithfully
mimicking the clonal genetic evolution observed in human
cancers. Newer models have leveraged multiple recombination
systems (Cre/loxP and FLP/FRT) to induce temporally separated
mutagenesis events33,34. Mutagenesis events can be coupled to
recombination-dependent ﬂuorescent reporters, to permit tracing
of genetically distinct clones35–37. By titrating down the dose and
altering the timing of recombinase expression, sporadic genetic
modulation can be induced. However, given that mutagenesis and
ﬂuorescent labelling occur through separate recombination
events, decreased recombinase activity enhances the likelihood
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Figure 7 | p53 loss promotes the initiation and expansion of low-grade PanINs. (a) Low-grade uniform colour PanINs from 6-week-old Pdx1-Cre-
K-MADM-p53 mice showing p53KO/KO (green, GFPþ/tdTomato ), p53WT/WT (red, GFP/tdTomatoþ ) and p53KO/WT (yellow, GFPþ/tdTomatoþ )
cells. Representative images of all-green and all-red PanINs are shown. Blue, DAPI-stained nuclei. Scale bars, 100 mm. (b) Absolute quantiﬁcation of
observed all-green and all-red low-grade PanINs from 6-week-old Pdx1-Cre-K-MADM-p53 mice (n¼ 5 mice total). Expected numbers are based on 1:1
stoichiometric ratio of green and red cell generation, and were not observed (Po0.001, w2-test). (c) Low-grade mixed-colour PanINs from 6-week-old
Pdx1-Cre-K-MADM-p53 mice showing green, red and yellow cells. Representative images of non-dominant, green-dominant and red-dominant low-grade
PanINs are shown. Blue, DAPI-stained nuclei. Scale bars, 100mm. (d) Absolute quantiﬁcation of observed green-dominant and red-dominant low-grade
PanINs from 6-week-old Pdx1-Cre-K-MADM-p53 mice (n¼ 5 mice total). Expected numbers are based on 1:1 stoichiometric ratio of green and red cell
generation, and were not observed (Po0.001, w2-test). A minority of low-grade PanINs (14 of 94) did not exhibit color dominance.
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of uncoupling of these events. In contrast, MADM-dependent
labelling and mutagenesis occur through a single recombination
event, maintaining the ﬁdelity of the correlation of ﬂuorescence
protein expression and genotype. Moreover, MADM generates
two genetically distinct subclonal population, permitting the
tracing of lineage-related tumour suppressor gene wild-type and
knockout clones within the same tumour.
By exploiting this feature of MADM, we have been able to
deﬁne when p53 functions to suppress lung and pancreatic
tumorigenesis. Genetic analyses on human cancers would suggest
that p53 functions late during tumour progression, as p53
mutations are principally identiﬁed in lung adenocarcinomas and
high-grade PanINs or PDAC rather than their lower-grade
precursors17,18. Our prospective evaluation of p53 wild-type and
knockout clones suggest that this is indeed true during lung
tumorigenesis and are consistent with experiments using p53
reactivation models14,15. In contrast, p53 suppresses both the
initiation and early expansion of pancreatic tumours. This
conclusion would not have been drawn from existing genomic
data from human tumours and validates the use of in vivo models
to understand the molecular and cellular features that govern
tumour progression.
The mechanisms that lead to differential induction of the
p19ARF-p53 axis in early lung and pancreatic tumours remain
unclear. In lung cancer, it is thought that enhanced oncogenic
stress through Kras ampliﬁcation and hyperactivation of
the mitogen-activated protein kinase pathway may trigger
p19ARF expression14,15. In contrast, Kras ampliﬁcation is rarely
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Figure 8 | p53 expression in various stages of lung and pancreatic tumour progression. (a) IHC for p53 in LSL-KrasG12D/KrasWT; p53LSL-R172H/ﬂox
low-grade adenomas and mixed-grade adenocarcinomas revealed p53 staining only in high-grade lung tumour cells. (b) IHC for p53 in Pdx1-Cre;
LSL-KrasG12D/KrasWT; p53LSL-R172H/WTadult pancreas revealed increased p53 expression in higher-grade pancreatic lesions. Arrows show low-grade PanINs.
(c) A subset of acinar-to-ductal metaplasia (ADM) cells expressed p53 (arrows). (d) A subset of low-grade PanIN cells expressed p53 (arrowheads). Scale
bars, 100mm (all).
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observed in pancreatic cancer. Instead, activation of
the phosphatidylinositol 3-kinase pathway downstream of
oncogenic Kras may play a greater role in activating p19ARF
during pancreatic tumorigenesis. Indeed, mutant PIK3CAH1047R
expression in the pancreas phenocopies oncogenic Kras in terms
of tumour progression and p19ARF expression38. In addition,
Cre-mediated deletion of the PI3K effector Pdk1 in Kras-initiated
pancreatic tumours reduces the induction of p19ARF38.
Alternatively, tissue-speciﬁc mediators of ARF induction could
also explain the differences in ARF expression between Kras-
driven lung and pancreatic tumours. These include additional
signalling pathways (for example, Notch39), epigenetic modiﬁers
(for example, Bmi1 (ref. 28)) and transcription factors (for
example, Dmp1 (ref. 40), AP-1 (ref. 41) and STAT3 (ref. 42)).
Nonetheless, the capacity of Pdx1-Cre; LSL-KrasG12D/KrasWT
mice to initiate tumours and develop high-grade pancreatic
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Figure 9 | p19ARF is expressed in early lesions during pancreatic but not lung tumorigenesis. (a) IHC for p19ARF in Pdx1-Cre; LSL-KrasG12D/KrasWT;
p53LSL-R172H/WT tumours showed expression throughout pancreatic tumorigenesis from early acinar-to-ductal metaplasia (ADM) and PanIN lesions to
PDAC. (b) IHC for p19ARF exhibited expression in LSL-KrasG12D/KrasWT; p53ﬂox/ﬂox lung adenocarcinomas but not adenomas. (c) IHC for p19ARF in
Pdx1-Cre; LSL-KrasG12D/KrasWT (KC) tumours, lacking p53mutation, displayed expression throughout pancreatic tumorigenesis. These data suggest that p53
mutation in a does not induce p19ARF by feedback upregulation, as has been previously described28. Scale bars, 100mm (all).
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lesions despite wild-type p53 and intact p19ARF expression
(Fig. 9c) supports the existence of non-genetic mechanisms
to evade p19ARF-p53-mediated tumour suppression. A better
understanding of these mechanisms may offer novel therapeutic
approaches to reinforce this tumour suppressive pathway to
prevent tumour initiation and progression.
In addition to our p53-related ﬁndings, our results offer the
ﬁrst in vivo experimental evidence of spontaneous intratumoral
dispersion of genetically distinct subclones during solid tumour
progression. Genomic studies have revealed that most cells within
a tumour harbour multiple truncal mutations with subclonal
genetic heterogeneity occurring late during tumorigenesis1,4–6.
How these truncal mutations propagate throughout a tumour
remains poorly understood, although a recent computational
model predicted intratumoral cell dispersion during tumour
growth as a potential mechanism43 and is consistent with
our ﬁndings. The mechanism that leads to this dispersion
phenomenon is unknown. Based on the overall low rates of
proliferation in low-grade tumours (Supplementary Fig. 3), we
hypothesize that labelled low-grade tumour cells divide at rates
comparable to neighbouring unlabelled cells permitting
intermingling after several rounds of cell division of both cell
types. In contrast, p53KO/KO cells that have progressed to higher
grade divide faster than surrounding cells, allowing them to form
more localized clusters. Alternative potential mechanisms for
subclonal cell dispersion in early lesions include intratumoral cell
migration, competition with neighbouring cells or immune cell
clearance. The development of new approaches that permit
long-term live in vivo imaging of these tumours could aid in
exploring these explanations using these models.
Methods
Animal studies. Animal studies were approved by the MIT Institutional Animal
Care and Use Committee. All animals were maintained on a mixed background.
MADM11-GT (Stock #013749), MADM11-TG (Stock #013751), Pdx1-Cre (Stock
#014647) and p53ﬂox/ﬂox (Stock #008462) mice were obtained from the Jackson
Laboratory. MADM11-TG,p53WT/MADM11-TG,p53WT mice were crossed with
p53KO/WT mice, which carry a p53-null allele lacking exons 2–6 (ref. 44).
Intercrossing the progeny MADM11-TG,p53WT/p53KO mice permitted
recombination of the p53-null mutation onto the same chromosome as the
MADM cassette. These MADM11-TG,p53KO/p53WT mice were subsequently
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Figure 10 | Extra- and intra-tumoral dispersal of early lung and pancreatic tumours. (a) p53KO/KO (green, GFPþ/tdTomato ) high-grade PanIN
with extra-tumoral dispersal of CK19-negative cells (arrows) in a 6-week-old Pdx1-Cre-K-MADM-p53 mouse. (b) Stitched confocal image of an entire lung
lobe from a 10-week-p.i. K-MADM-p53 mouse reveals multiple low-grade tumours, some harbouring ﬂuorescently labelled cells (arrowheads) and others
not (arrows). Most tumours showed dispersed labelling of green and red cells (white arrowheads), whereas some showed clusters of cells (yellow
arrowhead). Scale bar, 500 mm. (c) Lung adenoma from a 16-week-p.i. K-MADM-p53 mouse shows dispersed green, red and yellow cells. (d) Low-grade
PanIN from a 6-week-old Pdx1-Cre-K-MADM-p53 mouse shows dispersed green, red and yellow cells. (e) Three-dimensional (3D) rendering of
multi-photon imaging of a lung adenoma from a 16-week-p.i. K-MADM-p53 mouse showing non-contiguous green (arrows) and red (arrowheads) cells.
(f) 3D rendering of multi-photon imaging of a low-grade PanIN from a 6-week-old Pdx1-Cre-K-MADM-p53mouse showing dispersed green (arrows) and red
(arrowheads) cells. Blue, DAPI-stained nuclei. Scale bars, 100 mm (all, unless otherwise noted).
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crossed to MADM11-TG,p53WT/MADM11-TG,p53WT mice, to generate
MADM11-TG,p53WT/MADM11-TG,p53KO. These mice were crossed with
LSL-KrasG12D (ref. 32) mice to create LSL-KrasG12D/KrasWT; MADM11-TG,p53WT/
MADM11-TG,p53KO breeders.
Pdx1-Cre or KrasLA2,Rosa26-CreERT2/KrasWT,Rosa26-CreERT2 mice15,25
were crossed to MADM11-GT/MADM11-GT mice to produce Pdx1-Cre;
MADM11-GT/þ and KrasLA2,Rosa26-CreERT2/KrasWT; MADM11-GT/þ mice,
which were thereafter intercrossed to generate Pdx1-Cre; MADM11-GT/
MADM11-GT and KrasLA2,Rosa26-CreERT2/KrasWT,Rosa26-CreERT2; MADM11-
GT/MADM11-GT as breeders. LSL-KrasG12D/KrasWT; MADM11-GT,p53WT/
MADM11-TG-p53KO (K-MADM-p53), Pdx1-Cre; LSL-KrasG12D/KrasWT;
MADM11-GT,p53WT/MADM11-TG-p53KO (Pdx1-Cre-K-MADM-p53) and
control mice lacking LSL-KrasG12D (Pdx1-Cre-MADM-p53) or p53 mutation
(Pdx1-Cre-K-MADM) were generated by crossing the above breeders.
KrasLA2,Rosa26-CreERT2/KrasWT; MADM11-GT,p53WT/MADM11-TG-p53KO
(KrasLA2,Rosa26-CreERT2/KrasWT; MADM-p53) and KrasLA2,Rosa26-CreERT2/
KrasWT; MADM (lacking p53 mutation) mice were generated in parallel crosses.
Pdx1-Cre; LSL-KrasG12D/KrasWT (KC); p53LSL-R172H/WT, KC; p53ﬂox/WT, KC;
p53LSL-R172H/ﬂox and KC; p53ﬂox/ﬂox pancreatic cancer mice and LSL-KrasG12D/
KrasWT; p53LSL-R172H/ﬂox and LSL-KrasG12D/KrasWT; p53ﬂox/ﬂox lung cancer mice
were produced previously described11,13,20. Kaplan–Meier survival analyses were
performed using Prism (GraphPad Software, Inc.). Mice were genotyped using tail
DNA by the HotShot method. Genotyping primers and protocols are listed in
Supplementary Tables 1 and 2, respectively.
Lentivirus production and infection. Lentivirus was produced by co-transfection
of 293T cells with pPGK-Cre lentiviral backbone and packaging vectors
(delta8.2 and VSV-G) using TransIT LT-1 (Mirus Bio). Viral supernatant was
collected at 48 and 72 h after transfection, ﬁltered and concentrated by
ultracentrifugation. Virus was resuspended in OptiMEM, titered and administered
intratracheally to mice24.
Tamoxifen treatment of mice. KrasLA2,Rosa26-CreERT2/KrasWT; MADM-p53 and
KrasLA2,Rosa26-CreERT2/KrasWT; MADM (lacking p53 mutation) mice at 5–10
weeks of age were injected intraperitoneally with tamoxifen (Sigma) at a dose of
9mg per 40 g total body weight every other day for a total of three doses, to induce
CreERT2-mediated recombination.
Tissue preparation and histology. MADM mice were sacriﬁced by CO2
asphyxiation and perfused with cold 4% paraformaldehyde (PFA; Electron
Microscopy Sciences) in PBS. For proliferation studies, mice were intraperitoneally
injected with EdU (Setareh Biotech) 1.5 h before sacriﬁce. Tissues were dissected,
ﬁxed overnight with cold 4% PFA, cryoprotected with 30% sucrose and embedded
in OCT (Tissue-Tek). For whole-mount multi-photon imaging, ﬁxed tissues were
liberated from OCT by washing with PBS, incubated with 1 mgml 1 4,6-diami-
dino-2-phenylindole (DAPI; Life Technologies) for 1 h at room temperature (RT)
or overnight at 4 C and stored in cold PBS before imaging. For tissue section
analyses, 5–30 mm sections were cut using a Leica cryostat, air dried for 30–60min,
washed three times with PBS, stained with DAPI (Life Technologies) for 5min and
mounted in Vectashield (Vector Labs) before imaging. For immunoﬂuorescence
staining, sections were blocked with 0.5% PNB (Perkin Elmer) and stained with
primary antibody, donkey anti-rabbit Alexa 647 secondary antibody (Life
Technologies A-31573, 1:500) and DAPI before mounting in Vectashield. Rabbit
anti-CK19 (Abcam ab133496, 1:100) and rabbit anti-cleaved caspase-3 (Asp175)
(Cell Signaling Technologies 9664, 1:100) primary antibodies were used. EdU was
detected in tissue sections using a Click-iT EdU Alexa Fluor 647 Imaging Kit
(Thermo Fisher Scientiﬁc).
CLARITY samples were prepared as previously described26. Brieﬂy, MADM
mice were perfused with a hydrogel monomer solution (4% acrylamide, 0.05% Bis,
0.25% VA-044 initiator, 4% PFA and 0.05% saponin in PBS) and intact tissues were
ﬁxed in the same solution for 72 h at 4 C. Samples were degassed for 10min under
nitrogen, incubated at 37 C for 4 h, rotated in clearing solution (200mM boric acid
and 4% SDS pH 8.5) and subject to electrophoretic tissue clearing in a custom-built
chamber for 48 h at 55 C and 10–15V. Samples were incubated in 0.1% Triton
X-100 in PBS for 3 days followed by an additional 3 days in FocusClear
(CelExplorer Labs) before imaging.
IHC for p53 and p19ARF was performed as previously described15. Brieﬂy,
formalin-ﬁxed parafﬁn-embedded sections were stained with haematoxylin and
eosin or immunostained with rabbit anti-p53 (Novacastra NCL-p53-CM5p, 1:400)
or rat anti-p19ARF (Santa Cruz Biotech sc-32748, 1:100) using Impress secondary
antibody kits on a Thermo Scientiﬁc Autostainer 360. Endogenous wild-type
p53 was not detectable in tissue sections using this antibody; thus, p53 IHC
was performed on sections from mouse tumours harbouring a p53R172H mutation
exhibiting p53 protein accumulation due to loss of negative feedback.
Primary cell culture and immunocytochemistry. Pancreatic tumour cells
from Pdx1-Cre-K-MADM-p53 mice were dissociated using a protease cocktail
containing collagenase (Worthington), dispase (Roche) and trypsin-EDTA
(Invitrogen) in Hank’s balanced salt solution, quenched with fetal bovine serum
(Hyclone) and passed through a 100 mm ﬁlter (Falcon) before plating in DMEM
(CellGro) containing 10% fetal bovine serum and penicillin/streptomycin (VWR).
Cells were grown in culture for 2–3 days and subject to FACS analysis using a
Guava ﬂow cytometry system (Millipore). Stable GFPþ /tdTomato (green)
cell lines were obtained through serial passage and conﬁrmed to be p53KO/KO
by PCR genotyping of genomic DNA isolated using QuickExtract (Epicentre). For
immunocytochemistry, primary cultured cells were grown on glass coverslips, ﬁxed
with PFA, permeabilized with 0.2% Triton X-100, blocked with 5% BSA in PBS and
stained with rabbit anti-p53 primary antibody (Novacastra NCL-p53-CM5p,
1:200), donkey anti-rabbit Alexa 647 secondary antibody (Life Technologies
A-31573, 1:500) and DAPI before mounting onto glass slides with Vectashield.
Unlike with tissue sections, endogenous p53 was readily detectable by
immunoﬂuorescence on cultured cells.
Imaging. Live imaging of cultured cells was performed with a Nikon Eclipse
TE2000-U light microscope and SPOT RT3 camera. Immunocytochemistry and
immunoﬂuorescence tissue section images were obtained using an Andor camera
attached to a Nikon 80 Eclipse 80i ﬂuorescence microscope using  4,  10 and
 20 objectives. Additional immunoﬂuorescence tissue section images were
obtained with an Olympus FV1200 Laser Scanning Confocal Microscope with
 10,  20 and  30 objectives. Whole-mount images of intact ﬁxed tissues were
taken using a Nikon Eclipse TE2000-U dissecting light microscope and SPOT RT3
camera. CLARITY samples were imaged at a depth of up to 0.5mm using a Nikon
A1R Ultra-Fast Spectral Scanning Confocal Microscope. Multi-photon imaging
was performed on an Olympus FV1000MP inverted microscope with a  25,
numerical aperture 1.05 objective and a SpectraPhysics Maitai tai/sapphire laser at
840 nm. Collagen 1, collected as second harmonic-generated polarized light, DAPI,
green ﬂuorescent protein (GFP) and tdTomato images were collected in three
photomultiplier tubes (PMTs) with band-pass ﬁlters of 425/30, 425/45 and 607/70.
Optical sections 5 mm apart to a tissue depth of 100–200 mm were obtained. IHC
sections were imaged using a Nikon Digital Sight DS-U3 camera. Image processing,
including merging colour channels, three-dimensional reconstructions and movie
generation, was performed with ImageJ (NIH). Figure 5a,b were published with
permission from MIT.
Quantiﬁcation methods and statistical analyses. All lung adenomas (n¼ 132
total) from a single section from each of ﬁve lungs derived from K-MADM-p53
mice infected at 10-16 weeks p.i. with lentivirus were classiﬁed for colour dom-
inance as green-dominant (n¼ 38), red-dominant (n¼ 31) or no dominance
(n¼ 51). An additional 12 tumours contained no labelled cells or only yellow cells
without evidence of G2-X recombination. w2-Test of green-dominant and red-
dominant tumours was performed with the null hypothesis being an expected ratio
of 1:1. All green and red cells from a random subset of tumours from 10 weeks p.i.
(n¼ 9 tumours) and 16 weeks p.i. (n¼ 8 tumours) mice were quantiﬁed from
alternating 30 mm sections through entire tumours (total tumour diameter ranged
from 300 to 500mm). Green-to-red cell ratios were calculated for each tumour and
geometric means with 95% conﬁdence intervals were plotted. Total number of
single-labelled cells (sum of green and red cells) versus green-to-red cell ratio was
plotted for all tumours and R2 and P-values were calculated by linear regression.
For analyses of PanIN initiation and early expansion, all low-grade PanINs
(n¼ 92) from a single section from each of ﬁve pancreata derived from 6-week-old
Pdx1-Cre-K-MADM-p53 mice were classiﬁed for colour dominance as all green
(n¼ 19), green-dominant (n¼ 47), no dominance (n¼ 14), red-dominant (n¼ 10)
or all red (n¼ 2) (Fig. 7). w2-Test of all-green and all-red or green-dominant and
red-dominant low-grade PanINs was performed with the null hypothesis being an
expected ratio of 1:1. Green-dominant and red-dominant high-grade PanINs and
PDACs from these mice were analysed similarly.
For quantiﬁcation of EdU incorporation, lung adenomas (n¼ 28) and lung
adenocarcinomas (n¼ 3) were imaged using a  10 objective and the number of
DAPIþ and EdUþ nuclei were quantiﬁed using ImageJ for a single image per
lung adenoma and a total of eight images from lung adenocarcinomas (n¼ 3 mice).
The percentage of EdUþ /DAPIþ cells from each image was calculated, averaged
for each grade of tumour and compared by two-tailed Student’s t-test. For low-
grade PanINs,  10 objective images were obtained (n¼ 2 mice) and the number
of total GFPþ , EdUþ /GFPþ , total tdTomatoþ and EdUþ /tdTomatoþ were
manually counted. The percentage of EdUþ /GFPþ and EdUþ /tdTomatoþ
cells were calculated and compared by two-tailed Student’s t-test.
Tumour spectrum analysis was performed on KrasLA2/KrasWT mice by
analysing histologic sections from the lung and pancreas after sacriﬁce for
tumour-related morbidity. Some of these mice also harboured heterozygous or
homozygous mutations in Lep (leptin, ob) or Lepr (leptin receptor, db), although
these genotypes did not have an impact on the frequency of tumour types observed.
Cell-to-cell distance in lung adenomas was determined by calculating the mean
distance between labelled nuclei based on Delauney triangulation using the
Delauney Voronoi plugin for ImageJ. Two-dimensional mean distances were
calculated separately for all green and red cells within tumours (n¼ 31) from a
single tissue section from K-MADM-p53 mice infected at 10-16 weeks p.i. and
normalized to the mean distance between adjacent cells on the same image. Green
and red cell distances were compared by two-tailed paired Student’s t-test. Po0.05
was used as level of signiﬁcance for all statistical analyses.
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Data availability. The authors declare that the data that support the ﬁndings from
this study are available within the article and its Supplementary Information ﬁles or
available from the corresponding author upon request.
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